Full-Time

Leader – Soins primaires Contracting and Portfolio Lead

Contrats et gamme de produits, Primary Care

Posted on 9/30/2025

Deadline 10/14/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

CA$113.3k - CA$188.8k/yr

Pointe-Claire, QC, Canada

Hybrid

Employees are expected to work on-site 2.5 to 3 days per week.

Category
Medical, Clinical & Veterinary (1)
Requirements
  • University degree in Science, Health Sciences or Business
  • Minimum 5 years’ experience in contract management, portfolio strategy, or commercial operations
  • Strong understanding of Canadian healthcare procurement and contracting landscape
  • Excellent communication, negotiation, and analytical skills
  • A coaching mindset that is flexible in managing colleagues of different levels of experience
  • Accumulated experience of pharmaceutical marketing across the product life cycle
  • Experience inspiring, motivating, engaging, and leading a cross-functional team across a shared vision
  • Speaking and writing in French and English is important. Bilingualism (French and English): An advanced level of English, both spoken and written, is required to enable the individual to collaborate effectively with colleagues and partners located elsewhere in Canada and internationally daily as part of their responsibilities.
Responsibilities
  • Coaching, Leading, and Supporting a contracting and portfolio managers & analysts to help them ensure these complex portfolios meet their full commercial potential for Pfizer and for patients
  • Work with a great cross functional team of amazing professionals including regulatory, supply chain, medical, sales, access, Global, senior leadership, and corporate affairs
  • Continuously monitor key metrics and indicators to ensure the business can articulate its performance narrative to the organization and the region
  • Engaging with key external stakeholders with a forward-looking and partnership approach to enhance the Canadian procurement landscape
  • Working with your LT peers on building the vision and promise for how Primary Care will continue to demonstrate leadership within and outside of Pfizer.
Desired Qualifications
  • Strategic Thinking: having a 3 year vision of where the portfolio is going to proactively plan for the strategic interventions that will generate the best return, including leading the development, negotiation, and execution of contracts with Group Purchasing Organizations (GPOs), wholesalers, and hospital networks.
  • Building commercial relationships: taking on the challenge of managing a talented & high performing team, while building relationships with key partners
  • Networking: Collaborating, communicating, aligning with key internal and external stakeholders: Global, Pfizer Internal, GPOs and key hospital stakeholders
  • Leadership without Authority: Leading, collaborating, communicating, and aligning a diverse cross functional team and thriving in a matrix organization
  • Prioritization: both for you and your teams…ensuring everyone is focused on the right things and being deliberate on what you choose to do and choose not to do
  • Your Planning Skills: Pushing yourself to help your team manage competing priorities and having the foresight to create rhythm that will allow your teams to deliver what it needs to when it needs to
  • Communication Skills: You will need to clearly articulate the vision of the business, and your vision of what you expect so the organization knows where it is headed and why
  • Push for Innovation: challenge convention and ensure that teams feel empowered to take on ambitious breakthrough goals
  • Responsibility to Report: Identifies and reports adverse events and product complaints as per Corporate procedure, including Your Reporting Responsibilities (YRR) training.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Berobenatide could create a differentiated obesity franchise if Phase 3 succeeds.
  • The 25-valent pneumococcal vaccine can extend Pfizer's vaccine leadership beyond Prevnar.
  • AI licensing with Chai Discovery may accelerate early-stage drug design and hit rates.

What critics are saying

  • Eliquis, Ibrance, and Xtandi patent expirations will pressure revenue before replacements mature.
  • Berobenatide faces entrenched GLP-1 competition and a costly 10-plus-trial Phase 3 program.
  • Pfizer's oncology strategy depends on late-stage execution across dozens of programs and partnerships.

What makes Pfizer unique

  • Pfizer directs about 40% of R&D into oncology across five tumor areas.
  • Its oncology pipeline spans 50+ programs, 25+ new molecular entities, and 3 modalities.
  • HYMPAVZI is the first subcutaneous non-factor therapy for pediatric hemophilia B ages 6-11.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pfizer who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE